On October 20, Fox Business headlined a GLP-1 injection recall as nationwide. Apothecary Pharma’s recall, begun September 24, covers 23 vials, 22 of them compounded tirzepatide. The FDA rated it Class II and lists no illnesses. Fox Business hands the reader its scale first: GLP-1 injections, nationwide. The count waits in the text. Apothecary Pharma, a North Carolina compounding pharmacy, is recalling 23 vials: 22 of tirzepatide, the ingredient in Eli Lilly’s Mounjaro and Zepbound, and one NAD+ injection. The FDA rated it Class II, serious harm unlikely, and its notice lists no illnesses or injuries. The first size a mind is handed becomes the ruler for everything after it, the habit called anchoring. The headline is accurate: the vials went out nationwide and their sterility cannot be assured. What it leaves out is the base. Its ‘nationwide’ and Reuters’s ‘boom’ the next morning are sizes with no count, no period and no comparison behind them. The tell is a word of size standing where a number should be. The fear it raises lands on every GLP-1 injection, while the recall names one pharmacy’s vials. Three headlines from October 20 and 21 carry one market from three sides: a recall of copies, a push to close an import gap for knockoff retatrutide, and beauty firms selling a fix for ‘Ozempic face’. Since February 6 the FDA has moved against compounded GLP-1 ingredients and misleading ads, and on February 9 Novo Nordisk sued Hims & Hers. Each seller gains when the body reads as an emergency: the patent holder from fear of the copy, the copier from fear of the price.
